drugset / Trial / NCT04962724

A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants

NCT04962724

Phase 1 Completed 12 enrolled Debiopharm International SA
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of the study is to determine absorption, metabolism, and excretion of a single oral dose of \[14C\]-xevinapant. This information will enable assessment of absorption and clearance mechanisms of \[14C\]-xevinapant as well as identify metabolites. In addition, the study will allow to determine absolute bioavailability of xevinapant and understand its intravenous pharmacokinetics.

Timeline

Start
2021-08-02
Primary completion
2021-11-09
Completion
2021-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Xevinapant Small molecule 100 ug Oral
Subject Xevinapant Small molecule 200 mg Oral

Indications

No indication recorded.